open access

Ahead of print
Research paper (original)
Published online: 2024-01-04
Get Citation

Pancreatic cancer concomitant with other malignancies – single centre experience

Marta Fudalej12, Anna Badowska-Kozakiewicz1, Daria Kwaśniewska2, Izabella Cichowska3, Andrzej Deptała1
Affiliations
  1. Department of Oncology Propaedeutics, Medical University of Warsaw, Warsaw, Poland
  2. Department of Oncology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
  3. Department of Pathology, Military Institute of Medicine – National Research Institute, Warsaw, Poland

open access

Ahead of print
Original articles – Pancreatic cancer
Published online: 2024-01-04

Abstract

Introduction. Pancreatic cancer (PC) remains one of the most deadly tumours. The study aimed to describe a single-centre experience of PC concomitant with other malignancies.
Material and methods. Fifteen cases of PC associated with other primary malignancies were selected from the studied cohort. Statistical analysis with the usage of appropriate tests was conducted.
Results. Patients were presented with PC and other malignancies, encompassing breast, ovarian, colorectal, prostate, hepatocellular carcinomas, and thymoma. The median survival time was 75.0 months from the diagnosis of the first primary cancer and 14.0 months from the second primary cancer diagnosis. There was no significant difference in progression-free survival (p = 0.44) and overall survival (p = 0.28) between patients with and without a history of other malignancies.
Conclusions. The long-term follow-up examinations for oncological patients may allow the early diagnosis of concomitant malignancies. Nevertheless, results suggest that second primary tumours do not affect patients overall survival.

Abstract

Introduction. Pancreatic cancer (PC) remains one of the most deadly tumours. The study aimed to describe a single-centre experience of PC concomitant with other malignancies.
Material and methods. Fifteen cases of PC associated with other primary malignancies were selected from the studied cohort. Statistical analysis with the usage of appropriate tests was conducted.
Results. Patients were presented with PC and other malignancies, encompassing breast, ovarian, colorectal, prostate, hepatocellular carcinomas, and thymoma. The median survival time was 75.0 months from the diagnosis of the first primary cancer and 14.0 months from the second primary cancer diagnosis. There was no significant difference in progression-free survival (p = 0.44) and overall survival (p = 0.28) between patients with and without a history of other malignancies.
Conclusions. The long-term follow-up examinations for oncological patients may allow the early diagnosis of concomitant malignancies. Nevertheless, results suggest that second primary tumours do not affect patients overall survival.

Get Citation

Keywords

pancreatic cancer; oncology; survival

About this article
Title

Pancreatic cancer concomitant with other malignancies – single centre experience

Journal

Nowotwory. Journal of Oncology

Issue

Ahead of print

Article type

Research paper (original)

Published online

2024-01-04

Page views

68

Article views/downloads

33

DOI

10.5603/njo.97932

Keywords

pancreatic cancer
oncology
survival

Authors

Marta Fudalej
Anna Badowska-Kozakiewicz
Daria Kwaśniewska
Izabella Cichowska
Andrzej Deptała

References (32)
  1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016; 22(44): 9694–9705.
  2. Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technol Cancer Res Treat. 2020; 19: 1533033820962117.
  3. Zanini S, Renzi S, Limongi AR, et al. A review of lifestyle and environment risk factors for pancreatic cancer. Eur J Cancer. 2021; 145: 53–70.
  4. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7(4): e1000267.
  5. Piątek M, Nawrocki S. Locally advanced pancreatic cancer — new therapeutic challenges. Nowotwory. Journal of Oncology. 2016; 66(4): 312–316.
  6. Majos A, Durczyński A, Strzelczyk J. Very high and very low levels of preoperative absolute monocyte count indicate poor long-term survival outcomes in patients with pancreatic adenocarcinoma. A preliminary study. Nowotwory. Journal of Oncology. 2022; 72(5): 282–287.
  7. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer. 2011; 11: 83.
  8. Glicksman AS, Fulton JP. Metachronous cancer. R I Med J (2013). 2013; 96(4): 41–44.
  9. Jung JO, Nienhüser H, Schleussner N, et al. Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach. Int J Mol Sci. 2020; 21(3).
  10. Neugut A, Robinson E. Multiple primary neoplasms. The Cancer journal (Print. 1992; 5(5): 245–248.
  11. Shen M, Boffetta P, Olsen JH, et al. A pooled analysis of second primary pancreatic cancer. Am J Epidemiol. 2006; 163(6): 502–511.
  12. Shin SJ, Park H, Sung YN, et al. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Cancer Res Treat. 2018; 50(4): 1175–1185.
  13. Neugut A, Ahsan H, Robinson E. Pancreas cancer as a second primary malignancy. A population-based study. Cancer. 1995; 76(4): 589–592, doi: 10.1002/1097-0142(19950815)76:4<589::aid-cncr2820760408>3.0.co;2-9.
  14. Amin S, McBride RB, Kline JK, et al. Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers. Cancer. 2012; 118(5): 1244–1251.
  15. Rahimi E, Batra S, Thosani N, et al. Increased Incidence of Second Primary Pancreatic Cancer in Patients with Prior Colorectal Cancer: A Population-Based US Study. Dig Dis Sci. 2016; 61(6): 1652–1660.
  16. Chung JW, Chung MJ, Bang S, et al. Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer. Gut Liver. 2017; 11(5): 728–732.
  17. Missiaglia E, Jacobs B, D'Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014; 25(10): 1995–2001.
  18. Newcomb PA, Zheng Y, Chia VM, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res. 2007; 67(15): 7534–7539.
  19. Rosen MN, Goodwin RA, Vickers MM. mutated pancreatic cancer: A change is coming. World J Gastroenterol. 2021; 27(17): 1943–1958.
  20. Holter S, Borgida A, Dodd A, et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2015; 33(28): 3124–3129.
  21. Mocci E, Milne RL, Méndez-Villamil EY, et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev. 2013; 22(5): 803–811.
  22. Lorenzo Bermejo J, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol. 2004; 15(12): 1834–1841.
  23. Chatterjee N, Hartge P, Cerhan JR, et al. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev. 2004; 13(9): 1415–1421.
  24. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007; 25(12): 1489–1497.
  25. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002; 20(16): 3484–3494.
  26. Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med. 2015; 373(26): 2499–2511.
  27. Jacobs EJ, Chanock SJ, Fuchs CS, et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer. 2010; 127(6): 1421–1428.
  28. Jacobs EJ, Rodriguez C, Newton CC, et al. Family history of various cancers and pancreatic cancer mortality in a large cohort. Cancer Causes Control. 2009; 20(8): 1261–1269.
  29. Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 2007; 102(12): 2696–2707.
  30. Wang Li, Brune KA, Visvanathan K, et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18(11): 2829–2834.
  31. McWilliams RR, Bamlet WR, Rabe KG, et al. Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol. 2006; 4(9): 1143–1147.
  32. Gerdes B, Ziegler A, Ramaswamy A, et al. Multiple primaries in pancreatic cancer patients: indicator of a genetic predisposition? Int J Epidemiol. 2000; 29(6): 999–1003.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl